Evolution of HIV-Associated Lymphoma Over 3 Decades
Authors:
- Germaine ChiaGCGermaine Chia
- Alessia Dalla PriaAPAlessia Dalla Pria
- David J. PinatoDavid J. Pinato
- Kizzy ParkerKPKizzy Parker
- Mark NelsonMNMark Nelson
- Mark BowerMBMark Bower
Open Access
- 1 June 2016
- journal article
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
- Vol. 72 (2) , 177-183
Abstract
The emergence of combined antiretroviral therapy (cART) and improvements in the management of opportunistic infections have altered the HIV epidemic over the last 30 years. We aimed to assess changes to the biology and outcomes of HIV-associated lymphomas over this period at the national center for HIV oncology in the United Kingdom. Clinical characteristics at lymphoma diagnosis have been prospectively collected since 1986, along with details of lymphoma treatment and outcomes. The clinical features and outcomes were compared between 3 decades: pre-cART decade (1986-1995), early-cART decade (1996-2005), and late-cART decade (2006-2015). A total of 615 patients with HIV-associated lymphoma were included in the study: 158 patients in the pre-cART era, 200 patients in the early-cART era, and 257 patients in the late-cART era. In more recent decades, patients were older (P < 0.0001) and had higher CD4 cell counts (P < 0.0001) at lymphoma diagnosis. Over time, there has also been a shift in lymphoma histological subtypes, with an increase in lymphoma subtypes associated with moderate immunosuppression. The overall survival for patients with HIV-associated lymphoma has dramatically improved over the 3 decades (P < 0.0001). Over the last 30 years, the clinical demographic of HIV-associated lymphomas has evolved, and the outcomes have improved.Keywords
This publication has 46 references indexed in Scilit:
- Temporal Trends in Presentation and Survival for HIV-Associated Lymphoma in the Antiretroviral Therapy EraJNCI: Journal of the National Cancer Institute, 2013
- HIV-associated Hodgkin lymphoma during the first months on combination antiretroviral therapyBlood, 2011
- Cumulative incidence of cancer among individuals with acquired immunodeficiency syndrome in the United StatesCancer, 2010
- Non-Hodgkin lymphoma incidence in the Swiss HIV Cohort Study before and after highly active antiretroviral therapyAIDS, 2008
- Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphomaHaematologica, 2007
- Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDSBlood, 2006
- AIDS-Related Burkitt's Lymphoma Versus Diffuse Large-Cell Lymphoma in the Pre–Highly Active Antiretroviral Therapy (HAART) and HAART Eras: Significant Differences in Survival With Standard ChemotherapyJournal of Clinical Oncology, 2005
- Protease inhibitors potentiate chemotherapy-induced neutropeniaBlood, 2004
- AIDS-Related Primary Brain Lymphoma in Michigan, January 1990 to December 2000AIDS Patient Care and STDs, 2002
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958